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Abstract
Human bone marrow mesenchymal stem cells (BM-MSC) are multipotent progenitor cells that have transient
immunomodulatory properties on Natural Killer (NK) cells, Dendritic Cells (DC), and T cells. This study compared the use
of MSC isolated from bone marrow and fetal liver (FL-MSC) to determine which displayed the most efficient
immunosuppressive effects on T cell activation. Although both types of MSC exhibit similar phenotype profile, FL-MSC
displays a much more extended in vitro life-span and immunomodulatory properties. When co-cultured with CD3/CD28-
stimulated T cells, both BM-MSC and FL-MSC affected T cell proliferation by inhibiting their entry into the cell cycle, by
inducing the down-regulation of phospho-retinoblastoma (pRb), cyclins A and D1, as well as up-regulating
p27
kip1expression. The T cell inhibition by MSC was not due to the soluble HLA-G5 isoform, but to the surface expression
of HLA-G1, as shown by the need of cell-cell contact and by the use of neutralizing anti-HLA-G antibodies. To note, in a HLA-
G-mediated fashion, MSC facilitated the expansion of a CD4
low/CD8
low T subset that had decreased secretion of IFN-c, and
an induced secretion of the immunomodulatory cytokine IL-10. Because of their longer lasting in vitro immunosuppressive
properties, mainly mediated by HLA-G, and their more efficient induction of IL-10 production and T cell apoptosis, fetal liver
MSC could be considered a new tool for MSC therapy to prevent allograft rejection.
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Introduction
Mesenchymal stem cells (MSC) are multipotent stem cells able
to form bone, cartilage and other mesenchymal tissues [1]. MSC
can be isolated from several sources, including adult bone marrow
and fetal tissues [2,3,4,5, and 6]. Fetal and adult MSC share
several common characteristics, including a fusiform fibroblast-like
morphology and phenotype. The most accepted profile for MSC is
a lack of expression of hematopoietic (CD34 and CD45) and
endothelial (CD31) markers, and co-expression of CD105 (SH2),
CD90 (Thy-1), CD73 (SH3), CD44 (HCAM), CD166 (ALCAM),
and CD29 [1] as well as the recently described CD146 (MSCA-1)
[7]. Bone marrow MSC (BM-MSC) and fetal MSC (FL-MSC)
express human leukocyte antigen (HLA) class I molecules, but not
HLA class II antigens, CD80 or CD86 co-stimulatory molecules.
BM-MSC modulate hematopoiesis and can exert immune
regulatory functions, both in vivo and in vitro, on a wide range of
immunocompetent cells, including T cells [8,9,10,11,12,13,14,15],
NK cells [16,17,18], B cells [19], and dendritic cells (DC) [20,21].
The immunomodulatory properties of BM-MSC require cell-cell
contact as well as soluble factors, including interleukin (IL)-6 [22],
hepatocyte growth factor (HGF) [10], nitric oxide (NO) [23],
prostaglandin (PGE)-2 [17], indolamine 2,3 dioxygenase (IDO)
[17,24] and HLA-G [25,26]. HLA-G is a non-classical MHC class
Ib molecule with a low polymorphism, a restricted tissue
distribution, and tolerogenic functions that contribute to fetal-
graft tolerance via the maternal immune system and to human
allograft acceptance [27]. Four membrane-bound (HLA-G1 to -
G4) and three soluble (HLA-G5 to -G7) HLA-G isoforms have
been described that inhibit immune cellular functions. HLA-G
modulates immune responses by interacting with specific receptors
ILT-2, ILT-4 and KIR2DL4 [28]. The mechanism of action of
HLA-G is controversial: we have demonstrated that it inhibits cell-
cycle progression of allogeneic T cells [29], whereas others have
demonstrated that the HLA-G molecule induces T-cell apoptosis
through the Fas pathway [30]. In addition, the immunomodula-
tory properties of HLA-G have been mainly attributed to the
soluble isoform HLA-G5 [26]. In vivo, BM-MSC prevent graft-
versus-host disease [9,11], but they only delay for few days
allograft rejection in animals given heart-transplants [31].
Consequently several groups have isolated MSC from other
sources with the hope that these cells could display much more
efficient immunoregulatory functions [3,32]. In this study we have
compared immunoregulatory properties of MSC derived from
adult and foetal tissues. In addition, we have investigated the
involvement of HLA-G in this process. Herein, we show that BM-
MSC and FL-MSC express the membrane-bound HLA-G1
isoform that is directly involved in the inhibition of T cell
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the cell cycle, and favored the generation of a CD4
low/CD8
low T
subset with an impaired IFN-c secretion. Remarkably, FL-MSC
displays much longer-lasting immunomodulatory properties com-
pared to BM-MSC, and are more efficient at inducing T cell
apoptosis and secretion of the immunosuppressive cytokine IL-10.
Results
Adult and fetal MSC share potential and
immunosuppressive functions
After 14–18 days of culture in specific medium, both adult (BM-
MSC) and fetal MSC (FL-MSC) were all positive for CD90,
CD105, CD44, CD29, CD166, CD146 and CD73 specific MSC
markers (Figure 1A). They were negative for HLA class II and
CD80 co-stimulatory molecules and had a multipotent ability to
differentiate into adipocytes, chondrocytes, or osteocytes (data not
shown). To compare proliferation potential of fetal and adult MSC,
we evaluated their cumulative population doubling over 40–50
days, by performing cellular counts at confluence at each cell sub-
culture. Our results indicate that during 50 days BM-MSC had less
than 10 doublings, while FL-MSC underwent about 30 doublings,
showing that FL-MSC proliferate much faster than adult MSC
(Figure 1B-C). In order to compare regulatory properties between
adult bone marrow and fetal MSC, T cells were activated with
CD3/CD28 and co-cultured at different effector/target (E/T)
ratios (from 1:20 to 1:1) with BM-MSC or FL-MSC. CFSE assay
was used to evaluate lymphocytes proliferation. In the absence of
MSC,CD3/CD28-stimulated lymphocytes proliferated strongly.In
contrast, FL-MSC or BM-MSC prevented their proliferation. This
inhibition was dependent on the E/T ratio: the strongest effect was
observed with a 1:1 ratio (80% inhibition), but was still significant
with a 1:10 ratio (50% inhibition) (Figure 1D).
HLA-G is expressed in adult and fetal MSC
The regulatory properties displayed by both adult and fetal MSC
against T cells led us to investigate the mechanisms involved in this
ability. Recent results have suggested that human MSC produce the
Figure 1. Characterization proliferation potential and immunosuppressive functions of adult and fetal MSC. (a) Bone marrow MSC
(n=6), cultured between passage 2 and 4, and human fetal-liver MSC, cultured between passage 12 and 18 (n=5), were characterized by cell surface-
marker expression using flow cytometry. The gray curves indicate the corresponding negative mouse IgG1 or IgG2a antibodies. Data corresponds to
a typical staining of BM-MSC and FL-MSC. (b) Time course of cell growth in culture of BM-MSC and FL-MSC. 5610
4 of both MSCs were seeded in 6
wells plate (4610
3/cm
2). (c) Cell count of MSC after 6 days. Averages of three independent experiments are shown. (d) Activated lymphocytes
(stimulated with anti CD3 and anti CD28) were cultured in the presence of adult MSC (passage 2–4, n=3) or fetal MSC (passage 12–15, n=3) at
different T:MSC ratios (CFSE assay, 5 mM for 5 min at 37uC). Averages of six independent experiments are shown.
doi:10.1371/journal.pone.0019988.g001
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the regulation of T cell proliferation [33]. RT-PCR (Figure 2A)
and western blot analysis (Figure 2B) showed that adult and fetal
MSCexpresstranscriptsandproteinforHLA-G1,butnotforHLA-
G5 (antibody 4H84, specific for both HLA-G1 and HLA-G5
isoforms). In addition, flow cytometry analysis (Figure 2C) showed
that HLA-G can be expressed at both the cell surface and
intracellularly by both types of MSC. Dot blot assay using the
5A6G7 antibody specific for HLA-G5, also shows that HLA-G5
isoform was not detected in supernatant of MSC (compared to M8-
G5 melanoma cell line) (Figure 2D). Since soluble HLA-G has
been reported to be released by MSC [33], these results suggest that
membrane-bound HLA-G could be shedded and secreted from
MSC.To investigate this hypothesis, we treatedMSCwith phorbol-
myristate acetate (PMA), a powerful inducer of metalloproteases. As
shown in Figure 2E, PMA-treated MSC displayed decreased
HLA-G1 cell-surface expression, suggesting that HLA-G1 cell-
surface expression is sensible to proteolytic shedding process
dependent on metalloproteinase activity. PMA-induced down-
regulation of membrane-bound HLA-G1 expression was accom-
panied by a significant increase of HLA-G in the supernatant after
PMA treatment, as shown by an ELISA assay (Figure 2F).
HLA-G plays a critical role in T cell proliferation mediated
by MSC
We investigated whether HLA-G expressed by MSC could be
modulated during MLR. Our results show that HLA-G1, but not
HLA-G5, was strongly up-regulated in both MSCs during MLR
(Figure 3A). PBL harvested from MLR did not express HLA-G1/
5 protein. In addition, we show that soluble HLA-G, which was
weakly secreted by both MSCs (,40 U/ml), was increased
following MLR (Figure 3B). The inhibitory properties of MSC
were mainly cell-contact-dependent, as transwell cultures induced
a weaker inhibition of T cell proliferation compared to cell-contact
cultures (Figure 3C). Moreover, the effect was HLA-G-depen-
dent, since the addition of neutralizing antibody anti-HLA-G1/-
G5 (87G mAb) restored lymphocyte proliferation in cell-contact
cultures with both BM- and FL-MSC (from 71% to 34% and 61%
to 36%, respectively). The effect of HLA-G was evaluated by using
increasing dose of the blocking HLA-G mAb (87G) both on BM-
MSC and FL-MSC during MLR. The higher restoration of T cell
proliferation was observed by adding 20 mg/ml of the HLA-G
blocking antibody (87G) (Figure S1). The addition of 87G mAb
to transwell cultures did not significantly restore T cell prolifer-
ation, highlighting that other soluble factor than HLA-G could be
Figure 2. HLA-G expression in MSC. HLA-G was detected in BM-MSC and FL-MSC by using RT-PCR, western blot and flow cytometry. (a) The RT-
PCR products from BM-MSC and FL-MSC, as a result of using specific primers for HLA-G1 and HLA-G5, were analyzed on an agarose gel. A FON-57 cell
line and b-actin were used as positive controls for HLA-G1 and HLA-G5, and as a loading control, respectively. In other experiments, M8-G1 and M8-
G5 transfected melanoma cell lines were used as positive control. (b) Detection of HLA-G isoforms in BM-MSC (passage 2–4, n=3), FL-MSC (passage
12–15, n=3), M8-G5 or M8-G1 (positive control) by western blot with 4H84 mAb. The 39 kDa bands correspond to HLA-G1 and the 37 kDa to the
soluble form (the soluble HLA-G5 or the shed HLA-G1). (c) The same MSC were also stained at the cell surface or intracellularly with MEM-G/9-PE (filled
histograms), a specific anti-HLA-G antibody. (d) Dot blot analysis showed that MSC do not secretes soluble HLA-G (clone 5A6G7), compared to
melanoma M8-G5 cell line used as positive control. (e) To induce the shedding of the membrane bound HLA-G1, cells were treated or not with PMA
(10 ng/ml) for 12 h and their HLA-G expression was evaluated by flow cytometry. PMA induce the release of HLA-G from M8-G1 cells as well as BM-
MSC or FL-MSC, also confirmed by ELISA assay (f). Histogram indicated the percentage of decrease compared to the non treated cells (*P,0.01;
**P,0.005). Averages of three independent experiments are shown.
doi:10.1371/journal.pone.0019988.g002
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the isotype control IgG2A has no impact on the inhibitory
properties of MSC (Figure S1). In addition, we observed that
BM-MSC lost their immunoregulatory properties after 6–8
passages (40–50 days in culture), whereas FL-MSC maintained
their immunoregulatory functions for at least 25 passages (75–90
days in culture) Noteworthy, the decrease of MSC’s immunosup-
pressive properties was associated with a down-regulation of HLA-
G expression in aged BM-MSC (passages.9). In contrast, FL-
MSC maintained HLA-G expression even after passage 30
(Figure 3E). By starting with 5610
4 cells, 8–10610
6 BM-MSC
with preserved immunoregulatory functions can be produced
(before passage 9–11). In the same time interval more than 30–
35610
6 FL-MSC can be produced, and more than 55–70610
6
FL-MSC with preserved regulatory properties (before passage 30–
35). These results show that fetal MSC during their lifespan much
more immunoregulatory cells and display longer lasting regulatory
abilities compared to adult MSC.
Modulation of surface phenotype and cytokines
secretion on T cells mediated by MSC
We also asked whether MSC could modulate the phenotypic
and cytokine profile of activated lymphocytes. After MLR, we
observed a significant decrease in the percentage of CD4+ and
CD8+ T cells (Figure 4A–B) which was partially restored by the
anti-HLA-G blocking antibody (87G). We did not observe
significant modification of any other functional markers, such as
CD69 or CD25 (data not shown). In contrast, we have found that
MSC strongly down-regulated IFN-c production and increased
IL-10 secretion in activated T cells (Figure 4C). The addition of
87G anti-HLA-G mAb inhibited IL-10 up-regulation mediated by
adult and fetal MSC and efficiently restored IFN-c secretion
mediated by adult, but not fetal MSC. Other cytokines, such as IL-
4 and IL-5, were not modulated by the presence of BM-MSC or
FL-MSC (data not shown).
MSC inhibit entry into the T cell cycle
Because MSC inhibited T cell proliferation, we investigated the
mechanism involved in this impairment. By using the Annexin V-
FITC/PI (Figure 5A) and MTT assays (data not shown), we found
that BM-MSC did not significantly modify the level of apoptosis in
activated T cells, whereas we observed a significant and HLA-G-
independent increase in the number of apoptotic T cells after co-
culture with FL-MSC. In addition, only 20% of activated
lymphocytes were in G0/G1 phase, compared to the 80% of
resting cells (Figure 5B). On the contrary, both adult and fetal
MSC blocked activated cells in G0/G1 phase. The neutralizing
anti-HLA-G antibody 87G strongly restored the T cells
proliferation. When we analyzed the activation status of the
cyclin/cdk complex and the inhibitory kinase family during MLR,
the level of phospho-retinoblastoma (pRb) was elevated in
activated T cells, but was decreased when lymphocytes were co-
cultured with BM-MSC or FL-MSC (Figure 5C). Similarly, the
expression of cyclin D1 and cyclin A were decreased in activated
lymphocytes incubated with BM-MSC or FL-MSC when
compared to fully activated lymphocytes. In contrast, MSC
induced a strong up-regulation of p27
kip1, an inhibitor of cyclin-
dependent kinase involved in the regulation of the cell cycle. All
these effects were inhibited when a neutralizing anti-HLA-G (87G)
blocking antibody was added to the culture medium suggesting
that HLA-G play a critical role in the immunomodulatory
functions of BM-MSC and FL-MSC in regulating a balance
between inhibitory molecules and proliferating signals. Further-
more, although decreased, the expression of cyclin E was not
HLA-G-dependent, whereas cyclin B expression, which is
predominantly expressed during the G2/M phase of the cell
cycle, was not modified by MSC.
Materials and Methods
Ethics
Informed written approval was obtained from the INSERM
institutional review board for these studies. Pregnant women gave
written consent for the clinical procedure and for the use of blood
or tissue for research purposes according to the Declaration of
Helsinki.
Cytokines, Abs, and reagents
The surface phenotype of MSC was assessed using specific
FITC- or PE-conjugated monoclonal antibodies (mAb), such as
CD29, CD44, CD80, HLA-DR, HLA-ABC (Immunotools),
CD146 (Miltenyi), CD90, CD105, CD166 (R&D Systems), and
CD73 (BD Pharmingen), whereas CD3 (BD Pharmingen), CD4,
CD8, CD25, CD28, and CD69 (R&D Systems) were used to assess
the T-cell surface phenotype. Anti-HLA-G (4H84, IgG1 anti-
HLA-G1 recognizes an epitope present on the alpha-domain of
the heavy chain) as well as anti-cyclin A/B1/E/D1 and
retinoblastoma (Rb) protein antibodies were purchased from
Santa Cruz Biotechnologies (Tebu, Le Parray en Yvelines,
France). Anti-p27
kip1 was purchased from BD Pharmingen.
Neutralizing anti-HLA-G (87G, HLA-G1 and HLA-G5) and
MEM-G/9 (native form of human HLA-G1) as well as the specific
anti-HLA-G5 5A6G7 antibody were purchased from Exbio
(Prague, Czech Republic). Recombinant human basic fibroblast
growth factor (FGF) was obtained from Immunotools, whereas
anti-CD28 was obtained from eBioscience. Mytomicin, Phorbol
Myristate Acetate (PMA), and anti-CD3 (OKT-3) were obtained
from Sigma.
Generation of human adult and fetal mesenchymal stem
cells
Human fetal livers (range 7–9 weeks of gestation, n=7) were
obtained from eight women after voluntary or therapeutic
abortions. Informed written consent was obtained from the patient
in accordance with the Declaration of Helsinki, and tissue
collection and use were performed according to the guidelines
Figure 3. HLA-G plays a critical role in T cell-proliferation mediated by MSC. (a) Western blot analysis (4H84 and 5A6G7 mAbs) for HLA-G1
(39 kDa) and HLA-G5 (37 kDa) isoform after MLR (4 days). Following MLR, lymphocytes and MSC (passage 2–4 and 12–15 for adult and fetal cells,
respectively) were loaded separately. (b) Soluble HLA-G released by MSC after MLR (4 days) was evaluated by ELISA assay. Two PBL and four adult or
fetal MSC were used to evaluate HLA-G secretion. M8-G1 and M8-G5 melanoma cells were used as positive control for HLA-G1 and HLA-G5 isoform
protein (contained and secreted, respectively. (c) CFSE-labeled T cells were cultured with MSC (ratio T:MSC 5:1) directly (cell-cell contact) or in
transwell culture system. Neutralizing anti-HLA-G antibody (87G mAb) was added on days 0 and 2 (20 mg/ml), as previously reported [26]. (d) BM-MSC
lacks immunomodulatory properties after more than 8 passages of culture, whereas FL-MSC have a more prolonged inhibitory effect on T cells
proliferation which remains HLA-G dependant. (e) Western blot analysis of HLA-G1 (4H84 mAb) protein expression in BM-MSC (passage 3 and 10)
compared to FL-MSC (passage 10 and 25). Averages of three independent experiments are shown. Error bars represent the SD. P-values were
calculated using Student’s t-test. *P,0.05, ** P,0.01; ***P,0.001, ns=not statistically significant.
doi:10.1371/journal.pone.0019988.g003
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liver cells were prepared as described previously [32]. Bone
marrow samples were obtained from adult bone marrow aspirates
(45615 years, n=6) to isolate MSC. Briefly, bone marrow and
fetal mononuclear cells were isolated using a density Ficoll-Paque
gradient separation and plated at 1.6610
5cells/cm
2 in a-MEM
(Life Technologies). This was supplemented with 2 mM L-
glutamine, 1% penicillin/streptomycin solution (all from Gibco),
and 10% heat-inactivated fetal calf serum (FCS; PAA Laborato-
ries) (complete medium) at 37uC in air with 5% CO2. After three
days, non-adherent cells were discarded and the cells were plated
at 4610
3cells/cm
2 in a a-MEM complete medium supplemented
with bFGF (1 ng/ml). The medium was changed twice a week.
When the cells were 70–80% confluent, the MSC were harvested
by treating with trypsin-EDTA (Gibco) (passage 1) and were then
cultured in a aMEM complete medium. Between passages 2 and
3, the MSC assumed a homogeneous morphology and were
defined as cells positive for CD90, CD105, CD166, CD44, CD73,
and CD29 MSC characteristic markers, and negative for CD45,
CD14, and CD34. The bone marrow MSC at passage 2–4, and
the fetal MSC at passage 12–18, which were used in this study,
could be differentiated into chondrogenic, osteogenic, and
adipogenic cells (R&D Systems). To compare fetal and adult
MSC proliferation potential, their growth kinetics were evaluated
by counting cell numbers after each passage and by estimating the
cumulative population doubling over 30 days, as previously
described [4].
Cell isolation, mixed lymphocytes reaction (MLR) and
suppression assays
T cells were isolated from healthy volunteers (n=10) (Etablisse-
ment Franc ¸ais du Sang: Ho ˆpital S. Louis, Paris, France) and
cultured (1610
6 cells/ml) for 4 days with mitomycin-treated
(25 mg/ml, 30 min, 37uC) MSC, and were used as responder cells
to assess their proliferation. Briefly, freshly isolated T cells were
resuspended in PBS/FCS 5% and labeled with 5 mM 5,6
carboxyfluorescein diacetate succinimidyl ester (CFSE, Molecular
Probes, Eugene, OR) for 5 min at 37uC, as previously described
[34]. T cells stimulated with anti-CD3 (OKT-3, 500 ng/ml) and
anti-CD28 (1 mg/ml), in RPMI 1640 complete medium, were used
as a control for T-cell proliferation. Activated lymphocytes were
also co-cultured, with or without mitomycin-treated MSC, in 24-
well flat-bottom plates (ratio T/MSC, 5:1) for 4 days to evaluate
marker expression by flow cytometry. The biological effects of
Figure 4. MSC facilitate a CD4
low and CD8
low subset expansion that secrete IL-10. (a) Surface CD4 and CD8 expression in CFSE-stained
activated lymphocytes was evaluated by flow cytometry in the absence or presence of 20% adult and fetal MSC for 4 days. 87G anti-HLA-G antibody
was added to evaluate the involvement of HLA-G. One representative experiment is shown. (b) CD4 and CD8 expression of T cells incubated with
MSC (expressed as MFI, Mean Fluorescence Intensity) are presented. Error bars represent SD. P-values were calculated using Student’s t-test. *P,0.05,
**P,0.01; ***P,0.001, ns=not statistically significant. (c) CD3/CD28-activated T cells were cultured in the presence of BM-MSC and FL-MSC (passage
2–4 and 12–15 for adult and fetal cells, respectively) for 4 days and IL-4, IL-5, IFN-c and IL-10 production was evaluated by using ELISA assay. Averages
of four independent experiments are shown. P-values were calculated using Student’s t-test. *P,0.05, **P,0.01; ***P,0.001, ns=not statistically
significant.
doi:10.1371/journal.pone.0019988.g004
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neutralizing antibody (87G, 20 mg/ml, Exbio). T cell apoptosis
was evaluated with Annexin V-FITC/PI assay (Beckman
Coulters).
Cell lines
The HLA class I-positive M8 and FON melanoma cell line were
kindly provided by E. Carosella (Ho ˆpital Saint-Louis, Centre
HAYEM-CEA, Paris, France). M8 cells were transfected with a
full-length HLA-G5 cDNA (M8-HLA-G5) or HLA-G1 cDNA
(M8-HLA-G1) subcloned in vector pcDNA (Invitrogen Life
Technologies) and used as positive control for HLA-G5 and
HLA-G1 expression, respectively. Stable cell lines were selected
with Hygromycin (50 mg/ml) (Invitrogen Life Technologies) in
complete medium, as previously described [35,36].
Flow cytometry analysis
For surface-marker expression, cells were washed twice with
PBS and, after Fc receptors were blocked, the cells were stained
with saturating concentrations of the appropriate mAbs or isotype-
matched Ab control for 30 min at 4uC, in the dark. Thereafter,
cells were washed twice with PBS and kept at 4uC until analysis.
For indirect fluorescence, FITC-conjugated anti-mouse was used
as a secondary Ab (30 min at 4uC in the dark). For HLA-G
intracellular staining, cells were permeabilised using a Cytoperm/
Cytofix kit (BD Pharmingen). Cell cycle was determined in
activated lymphocytes by washing cells with PBS and fixing them
in 70% ethanol at 220uC until use. Fixed cells were washed with
PBS and incubated with 0.5 mg/ml RNase A and 50 mg/ml
propidium iodide for 30 min. Cells were analyzed using
FACScan
TM (BD Biosciences, Franklin, NJ, USA), with CellQuest
Analysis (BD Biosciences) and FlowJo software (TreeStar).
Western Blotting
After 4 days of MLR, T cells were analyzed for cell cycle protein
expression. HLA-G in both MSCs was detected with an anti-
HLA-G1/G5 antibody (clone 4H84) or with an anti-HLA-G5
(clone 5A6G7). Cells were lysed and the pellets (30 mg/lane) were
resuspended in SDS-PAGE sample buffer, and analyzed using 7–
12% SDS-PAGE. The resolved proteins were transferred onto
nitrocellulose membranes (Bio-Rad), which were then saturated
for 1 h and incubated with the specific monoclonal antibody in
Figure 5. MSC regulates cell cycle entry of T cells, but do not induce cell apoptosis. Activated T cells were cultured with MSC (ratio T:MSC
of 5:1) for 4 days. (a) Activated T cells were cultured with fetal and adult MSC to evaluate their apoptosis activities using the Annexin-V/PI assay. (b)
Distribution of the G0–G1 phase in activated lymphocytes, as assessed by flow cytometry. (c) Expression of p27
Kip1, pRb, and cyclins A, E, B and D1
were evaluated by western blot analysis. GAPDH was used as a loading control. Averages of four independent experiments are shown. Error bars
represent SD. P-values were calculated using Student’s t-test. *P,0.05, **P,0.01; ***P,0.001, ns=not statistically significant.
doi:10.1371/journal.pone.0019988.g005
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TBS-0.01% Tween-20, and were then incubated with HRP-
conjugated goat anti-mouse IgG (Biotest Diagnostics, 1:1500). An
ECL detection system (ECL kit; Amersham Biosciences, Orsay,
France) was used according to the manufacturer’s instructions.
Quantification of the protein blotted was determined using
Fujifilm Intelligent Dark Box II and Image Gauge version 4.0
software.
RT-PCR analysis for human HLA-G
Total RNA was isolated from MSC pellets using RNeasy Micro
kit (Qiagen, France), according to the manufacturer’s instructions,
and quantified using a Nanodrop ND-100 (Nanodrop technolo-
gies, CA). One microgram of total RNA was incubated for 30 min
at 37uC with 0.2 U RQ1 DNAse (Promega, Madison, WI) in
reverse transcriptase (RT) buffer (Gibco, Life Technologies) in a
final volume of 20 ml. M-MLV RT (Gibco) was added, and the
mixture was further incubated for 1 h at 37uC. The volume of
cDNA was then adjusted up to 200 ml. cDNA were separately
amplified in a total volume of 50 ml containing 200 mM each
dNTP (Invitrogen), 5 ng/ml of each primer, and 2 U of Taq DNA
polymerase (Eppendorf, Germany). PCR was carried out with a
Mastercycler epgradient S (Eppendorf) for 35 cycles (1 min at 94uC,
1 min at 57uC, 1 min at 72uC) with a final extension at 72uC for
10 min. 5 mL of sample was used with primers specific for b-actin
and 10 ml with primers specific for HLA-G isoforms, as previously
described [37].
Cytokine detection by an enzyme-linked immunosorbent
assay (ELISA)
Cultured cell supernatants were harvested after 4 days of co-
culture and tested in triplicate for production of IFN-c, IL-4 and
IL-10 (eBioscience), HLA-G5 (clone 5A6G7) and total HLA-G
(both from Exbio) and IL-5 (R&D Systems) by ELISA, according
to the manufacturer’s instructions. The ELISA plates were read at
OD450 on a Microplate ELISA reader (Titertek multiskan plus,
Puteaux, France).
Data analyses
All experiments were performed in at least three independent
assays, which yielded highly comparable results. Data were
presented as mean +/2 SD. The statistical significance (P values)
of the results was calculated using the two-tailed Student’s t-test. A
P,0.05 was considered statistically significant.
Discussion
BM-MSC have recently emerged as a therapeutic tool in
regenerative therapy and transplantation. Their use is based on
their plasticity and immunoregulatory properties. Because of their
hypoimmunogenicity and their potential to create an immuno-
suppressive local microenvironment through the production of
TGF-b, PGE-2, and HLA-G molecules [8,38], BM-MSC are
successfully employed to prevent graft-versus-host disease (GvHD)
[11,39,40]. However, because of their transient immunoregulatory
properties in transplantation models [26], we and others have
attempted to identify new populations of MSC that can exert
longer-lasting immunoregulatory properties [3]. Our data show
that fetal liver MSC could be a good alternative to BM-MSC.
Indeed, even though adult and fetal MSC exhibit a similar
morphology and phenotype, FL-MSC are also characterized by: 1)
faster growing kinetics than bone marrow MSC (30 vs. 8
doublings, respectively) with higher number of cells produced
over the same period, 2) a prolonged synthesis of HLA-G and 3) a
longer inhibition of T cell proliferation (.30 passages) compared
to BM-MSC (,8 passages).
It has been previously reported that the in vitro life span of
human fibroblasts is inversely related to donor’s age and that the in
vitro aging process is much more rapid for adult than fetal
fibroblasts [41–42]. Herein, on the basis of the total number of
population doublings (PD) performed and the total number of cells
produced, we observed that BM-MSC undergo in vitro aging much
more rapidly than FL-MSC. However, the loss of HLA-G
expression and the decrease of regulatory functions were not
associated with a significant decrease of proliferation potential of
these cells. In addition, we did not observe any up-regulation of
p16
INK4A, a marker of senescence, in BM-MSC until passage 10,
suggesting that our cells did not undergo massive senescence
process [43]. In contrast, fetal MSC maintained long-lasting
immunoregulatory properties. These results are complementary
with those of Guillot et al., who demonstrated that FL-MSC grow
faster and have longer telomeres than adult MSC [4], which is
associated with a longer cellular longevity [44]. These properties
render FL-MSC very attractive for therapeutic purposes, for which
a rapid expansion as well as a great number of cells and prolonged
immunoregulatory properties are required.
Our data show that both MSC populations inhibit T cell
proliferation, mainly through cell-cell contacts involving the
membrane isoform of the immunosuppressive molecule, HLA-
G1, but not the soluble HLA-G5 isoform [26,33, and 45]. RT-
PCR analysis clearly indicates that both fetal and adult MSC
expressed HLA-G1, but not the HLA-G5 transcript. Moreover,
western blot analysis performed on total cell lysate revealed
expression of the HLA-G1-specific 39 kDa band, but not the
HLA-G5-specific 37 kDa band. However, we observed that HLA-
G1 protein can be shedded and released by MSC incubated with
PMA, which activates metalloproteases. This may explain the
presence of the 37 kDa band (molecular weight of shed HLA-G1)
in a previous publication [26]. To note, we found increased HLA-
G1 protein expression in both MSCs after MLR, whereas HLA-
G5 isoform was not found at basal levels, or after MLR. The
increase of HLA-G1 was more important for FL-MSC than adult
MSC. ELISA assays revealed that both MSC secrete very low
levels of HLA-G (shed HLA-G), but its concentration was
increased by their co-culture with T cells. However, the increased
amount of secreted HLA-G was not enough to significantly inhibit
lymphocyte proliferation in transwell experiments. The implica-
tion of HLA-G in controlling T cell response was demonstrated by
the restoration of T cell proliferation in the presence of a
neutralizing anti-HLA-G antibody in cell-cell contact conditions
but not in transwell system cultures, which displays a residual
HLA-G-independent inhibitory activity on T cell function. Both
fetal and adult MSC strongly impaired T cell proliferation mainly
by preventing the early phase of T cell cycle entry, by inducing a
down-regulation of molecules that trigger the G0–G1 transition,
such as the pRb protein or the cyclins A and D1, or by up-
regulating molecules that inhibit this process, such as the p27
kip1
protein. These events are reversed in the presence of the HLA-G
blocking antibody (87G mAb), whereas the down-regulation of
cyclin E expression was HLA-G-independent. Importantly, cyclin
B expression, which is predominantly expressed during the G2/M
phase of the cell cycle, was not modified by MSC. This highlights
the fact that both adult and fetal MSC principally block the early
G0/G1 transition phase of activated T cells.
Interestingly, it has been reported in vivo that a subset of double-
transplanted patients showed improved graft acceptance which
was associated with a high serum level of HLA-G and the
expression of regulatory T cells, which synthesized IL-10 and have
Adult and Fetal MSC Block Lymphocytes Cell Cycle
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+/CD4
low and CD3
+/CD8
low phenotype [33,46]. In our
experimental model, both MSCs consistently facilitated the HLA-
G-dependent appearance of CD3
+/CD4
low and CD3
+/CD8
low
with impaired IFN-c secretion. However, the decrease of IFN-c
secretion was less pronounced in FL-MSC. This could correlate
with the lower expression of HLA-G in FL-MSC at the basal level
(before MLR), suggesting that the inhibitory effect on the IFN-c
secretion could be delayed until HLA-G expression is sufficiently
produced by MSC or depend on the production of other unknown
factors by FL-MSC compared to adult MSC. Both MSCs induced
IL-10 secretion, but only FL-MSC raised biologically relevant
concentration. Interestingly, it must be noted that FL-MSC but
not BM-MSC induced significant levels of T cell apoptosis through
a HLA-G-independent mechanism.
In summary, our results provide evidence that FL-MSC
represent an attractive alternative to adult BM-MSC in the
prevention of allograft rejection since they display several
distinguish features that render these cells immunotolerants.
Supporting Information
Figure S1 Evaluation of optimal concentration and
specificity of anti-HLA-G 87G. CFSE-labeled T cells were
cultured with MSC (ratio T:MSC 5:1) for 4 days. a) Involvement
of HLA-G was evaluated using neutralizing anti-HLA-G (87G
mAb) added on days 0 and 2 titrated at different concentrations.
(b) The specificity of the 87G was verified with the corresponding
antibody isotype control (10 mg/ml). Optimal concentration of
87G anti-HLA-G was obtained at 20 mg/ml for both MSCs.
Averages of three independent experiments are shown. Error bars
represent the SD. P-values were calculated using Student’s t-test.
ns=not statistically significant.
(TIF)
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